...
首页> 外文期刊>Neuro-ophthalmology >Papillophlebitis: Treatment of Vision Loss Due To Subretinal Fluid with Intravitreal Ranibizumab
【24h】

Papillophlebitis: Treatment of Vision Loss Due To Subretinal Fluid with Intravitreal Ranibizumab

机译:乳头状静脉炎:玻璃体内雷珠单抗治疗因视网膜下液引起的视力丧失

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

There are no specific treatment protocols for papillophlebitis, which is basically a central retinal vein occlusion (CRVO) occurring in young adults. The present report is that of a 14-year-old girl, who presented with blurred vision in her right eye. Although her visual acuity (VA) was initially 20/20, there were venous engorgements, blurry disc margins, and a substantial collection of subretinal fluid. She was diagnosed with papillophlebitis. When, 2 weeks later, her VA had decreased to 20/200, she was administered intravitreally injected ranibizumab. One week post-injection, her VA had returned to normal (20/20) and the subretinal fluid had diminished markedly. Intravitreal ranibizumab injection appears to be an effective treatment modality for this condition.
机译:没有针对乳头状静脉炎的具体治疗方案,乳头状静脉炎基本上是年轻人中发生的视网膜中央静脉阻塞(CRVO)。本报告是一个14岁女孩的报告,她的右眼视力模糊。尽管她的视力(VA)最初为20/20,但仍有静脉充血,椎间盘边缘模糊和大量视网膜下液。她被诊断出患有乳头状静脉炎。 2周后,当她的VA降至20/200时,进行玻璃体内注射兰尼单抗治疗。注射后一周,其VA恢复至正常水平(20/20),视网膜下液明显减少。玻璃体内雷珠单抗注射似乎是这种情况的有效治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号